Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Generated: April 19, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020717

« Back to Dashboard

NDA 020717 describes PROVIGIL, which is a drug marketed by Cephalon and is included in one NDA. It is available from ten suppliers. There is one patent protecting this drug. Additional details are available on the PROVIGIL profile page.

The generic ingredient in PROVIGIL is modafinil. There are twenty-six drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the modafinil profile page.

Summary for 020717

Tradename:	PROVIGIL
Applicant:	Cephalon
Ingredient:	modafinil
Patents:	1
Therapeutic Class:	Central Nervous System Agents
Formulation / Manufacturing:	see details

Pharmacology for NDA: 020717

Physiological Effect	Central Nervous System Stimulation Increased Sympathetic Activity

Suppliers and Packaging for NDA: 020717

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
PROVIGIL	modafinil	TABLET;ORAL	020717	NDA	Rebel Distributors Corp	21695-234	E	21695-234-30
PROVIGIL	modafinil	TABLET;ORAL	020717	NDA	Rebel Distributors Corp	21695-234	E	21695-234-15

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	100MG
Approval Date:	Dec 24, 1998	TE:	AB	RLD:	Yes
Patent:	➤ Try a Free Trial	Patent Expiration:	May 29, 2024	Product Flag?		Substance Flag?		Delist Request?	Y

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	200MG
Approval Date:	Dec 24, 1998	TE:	AB	RLD:	Yes
Patent:	➤ Try a Free Trial	Patent Expiration:	May 29, 2024	Product Flag?		Substance Flag?		Delist Request?	Y

Expired US Patents for NDA 020717

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cephalon	PROVIGIL	modafinil	TABLET;ORAL	020717-001	Dec 24, 1998	➤ Try a Free Trial	➤ Try a Free Trial
Cephalon	PROVIGIL	modafinil	TABLET;ORAL	020717-001	Dec 24, 1998	➤ Try a Free Trial	➤ Try a Free Trial
Cephalon	PROVIGIL	modafinil	TABLET;ORAL	020717-002	Dec 24, 1998	➤ Try a Free Trial	➤ Try a Free Trial
Cephalon	PROVIGIL	modafinil	TABLET;ORAL	020717-001	Dec 24, 1998	➤ Try a Free Trial	➤ Try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.